Marker Therapeutics, Inc. — Director's Dealing 2015

Jun 18, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TAPIMMUNE INC (TPIV)
CIK: 0001094038
Period of Report: 2015-06-16

Reporting Person: Eastern Capital LTD (10% Owner)
Reporting Person: Portfolio Services Ltd. (10% Owner)
Reporting Person: DART KENNETH BRYAN (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-06-16	Common Stock	X	5000000	$0.50	Acquired	10000000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-06-16	Series C-1 Warrant	$0.5	X	5000000	Disposed	2020-03-09	Common Stock (5000000)	Direct

Footnotes

F1: 5,000,000 of the reported securities are included within 5,000,000 Units. Each Unit, as amended pursuant to the Amended and Restated Restructuring Agreement dated June 2, 2015, consists of one share of common stock, one Series A-1 Warrant exercisable in whole or in part to acquire up to 5,000,000 shares of common stock, one Series B-1 Warrant exercisable in whole or in part to acquire up to 10,000,000 shares of common stock, one Series C-1 Warrant exercisable in whole or in part to acquire up to 10,000,000 shares of common stock, one Series D-1 Warrant exercisable in whole or in part to acquire up to 5,000,000 shares of common stock and one Series E-1 Warrant exercisable in whole or in part to acquire up to 5,000,000 shares of common stock

F2: Each Series C-1 Warrant allows the Reporting Persons to acquire up to 10,000,000 shares of common stock of the Issuer at an exercise price per share of $0.50 during the exercise period from March 9, 2015 until March 9, 2020. The Issuer may force the exercise of Series C-1 Warrant in the event that the closing price of the common stock is above $1.00 for 10 consecutive trading days (subject to certain conditions including minimum trading volume requirements and the non-occurrence of an Equity Conditions Failure).

F3: On June 16, 2015, Eastern Capital Limited exercised part of the Issuer's Series C-1 Warrant at an exercise price of $0.50 per share and acquired an additional 5,000,000 shares of common stock. Following the transaction, the Series C-1 Warrant held by the Reporting Persons is exercisable in whole or in part to acquire up to 5,000,000 shares of common stock.